Raymond Allan

Dr. Raymond Allan

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2017 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
HKHyun Koo
Hyun Koo
RARaymond Allan
Raymond Allan
RHRobert P. Howlin
Robert P. Howlin
PSPaul Stoodley
Paul Stoodley
LHLuanne Hall-Stoodley
Luanne Hall-Stoodley

1 September 2017 in Molecular Therapy
Verified
Journal Article
Open access
RHRobert P. Howlin
Robert P. Howlin
KCKatrina Cathie
Katrina Cathie
LHLuanne Hall-Stoodley
Luanne Hall-Stoodley
VCVictoria Cornelius
Victoria Cornelius
CDCaroline Duignan
Caroline Duignan
JWJeremy S. Webb
Jeremy S. Webb
Despite aggressive antibiotic therapy, bronchopulmonary colonization by Pseudomonas aeruginosa causes persistent morbidity and mortality in cystic fibrosis (CF). Chronic P. aeruginosa infection in the CF lung is associated with structured, antibiotic-tolerant bacterial aggregates known as biofilms. We have demonstrated the effects of non-bactericidal, low-dose nitric oxide (NO), a signaling molecule that induces biofilm dispersal, as a novel adjunctive therapy for P. aeruginosa biofilm infection in CF in an ex vivo model and a proof-of-concept double-blind clinical trial. Submicromolar NO concentrations alone caused disruption of biofilms within ex vivo CF sputum and a statistically significant decrease in ex vivo biofilm tolerance to tobramycin and tobramycin combined with ceftazidime. In the 12-patient randomized clinical trial, 10 ppm NO inhalation caused significant reduction in P. aeruginosa biofilm aggregates compared with placebo across 7 days of treatment. Our results suggest a benefit of using low-dose NO as adjunctive therapy to enhance the efficacy of antibiotics used to treat acute P. aeruginosa exacerbations in CF. Strategies to induce the disruption of biofilms have the potential to overcome biofilm-associated antibiotic tolerance in CF and other biofilm-related diseases.

1 November 2014 in Journal of Infection
Verified
Journal Article
Closed access
MWMatthew Wilkins
Matthew Wilkins
LHLuanne Hall-Stoodley
Luanne Hall-Stoodley
RARaymond Allan
Raymond Allan
SFSaul N. Faust
Saul N. Faust

1 May 2005 in International Journal of Systematic and Evolutionary Microbiology
Verified
Journal Article
Open access
RARaymond Allan
Raymond Allan
LLL. Lebbe
L. Lebbe
JHJ. Heyrman
J. Heyrman
PVP. De Vos
P. De Vos
CBC. J. Buchanan
C. J. Buchanan
NLN. A. Logan
N. A. Logan
Thirteen strains of endospore-forming bacteria were isolated from geothermal soils at Cryptogam Ridge, the north-west slope of Mt Melbourne, and at the vents and summit of Mt Rittmann in northern Victoria Land, Antarctica. 16S rRNA gene sequencing, SDS-PAGE and routine phenotypic characterization tests indicated that the seven isolates from the north-west slope of Mt Melbourne represent a novel species ofBrevibacillusand that the six isolates from Cryptogam Ridge and the vents and summit of Mt Rittmann represent a novel species ofAneurinibacillus.Brevibacillusstrains were not isolated from the sites at Mt Rittmann or Cryptogam Ridge andAneurinibacillusstrains were not isolated from the north-west slope of Mt Melbourne. Preliminary metabolic studies revealed thatl-glutamic acid, although not essential for growth, was utilized by both species. TheBrevibacillusspecies possessed an uptake system specific forl-glutamic acid, whereas theAneurinibacillusspecies possessed a more general uptake system capable of transporting other related amino acids. Both species utilized a K+antiport system and similar energy systems for the uptake ofl-glutamic acid. The rate of uptake by theBrevibacillusspecies type strain was 20-fold greater than that shown by theAneurinibacillusspecies type strain. The namesBrevibacillus levickiisp. nov. andAneurinibacillus terranovensissp. nov. are proposed for the novel taxa; the type strains are Logan B-1657T(=LMG 22481T=CIP 108307T) and Logan B-1599T(LMG 22483T=CIP 108308T), respectively.

1 March 2017 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
MDMatthew S. Dryden
Matthew S. Dryden
JCJonathan Cooke
Jonathan Cooke
RSRami J. Salib
Rami J. Salib
RHRebecca E. Holding
Rebecca E. Holding
TBTimothy Biggs
Timothy Biggs
MRMalcolm D. Richardson
Malcolm D. Richardson
Reactive oxygen species (ROS) is a novel therapeutic strategy for topical or local application to wounds, mucosa or internal structures where there may be heavy bacterial bioburden with biofilm and chronic inflammation. Bacterial biofilms are a significant problem in clinical settings owing to their increased tolerance towards conventionally prescribed antibiotics and their propensity for selection of further antibacterial resistance. There is therefore a pressing need for the development of alternative therapeutic strategies that can improve antibiotic efficacy towards biofilms. ROS has been successful in treating chronic wounds and in clearing multidrug-resistant organisms, including methicillin-resistant Staphylococcus aureus (MRSA), and carbapenemase-producing isolates from wounds and vascular line sites. There is significant antifungal activity of ROS against planktonic and biofilm forms. Nebulised ROS has been evaluated in limited subjects to assess reductions in bioburden in chronically colonised respiratory tracts. The antibiofilm activity of ROS could have great implications for the treatment of a variety of persistent respiratory conditions. Use of ROS on internal prosthetic devices shows promise. A variety of novel delivery mechanisms are being developed to apply ROS activity to different anatomical sites.

30 October 2020 in npj Biofilms and Microbiomes
Verified
Journal Article
Open access
PDF file
AVAdithi R. Varadarajan
Adithi R. Varadarajan
RARaymond Allan
Raymond Allan
JVJules D. P. Valentin
Jules D. P. Valentin
OOOlga E. Castañeda Ocampo
Olga E. Castañeda Ocampo
VSVincent Somerville
Vincent Somerville
Christian AhrensChristian Ahrens
Christian Ahrens
Pseudomonas aeruginosaMPAO1 is the parental strain of the widely utilized transposon mutant collection for this important clinical pathogen. Here, we validate a model system to identify genes involved in biofilm growth and biofilm-associated antibiotic resistance. Our model employs a genomics-driven workflow to assemble the complete MPAO1 genome, identify unique and conserved genes by comparative genomics with the PAO1 reference strain and genes missed within existing assemblies by proteogenomics. Among over 200 unique MPAO1 genes, we identified six general essential genes that were overlooked when mapping public Tn-seq data sets against PAO1, including an antitoxin. Genomic data were integrated with phenotypic data from an experimental workflow using a user-friendly, soft lithography-based microfluidic flow chamber for biofilm growth and a screen with the Tn-mutant library in microtiter plates. The screen identified hitherto unknown genes involved in biofilm growth and antibiotic resistance. Experiments conducted with the flow chamber across three laboratories delivered reproducible data onP. aeruginosabiofilms and validated the function of both known genes and genes identified in the Tn-mutant screens. Differential protein abundance data from planktonic cells versus biofilm confirmed the upregulation of candidates known to affect biofilm formation, of structural and secreted proteins of type VI secretion systems, and provided proteogenomic evidence for some missed MPAO1 genes. This integrated, broadly applicable model promises to improve the mechanistic understanding of biofilm formation, antimicrobial tolerance, and resistance evolution in biofilms.